ArticleTransfusion2026
Massive fetomaternal hemorrhage and successful prevention of maternal RhD alloimmunization: A case report.
Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMassive fetomaternal hemorrhage can lead to significant fetal morbidity or mortality. RhD negative patients require appropriate treatment to prevent alloimmunization in subsequent pregnancies. Few cases with follow-up into future pregnancies have been reported. CASE REPORT AND
results30-year-old gravida 3 para 1 presented at 40 weeks and 2 days gestation for late term evaluation. Ultrasonography identified an intrauterine fetal demise. The patient was O RhD negative and had previously received Rh immunoglobin (RhIG) at 26 weeks of gestation. The patient was induced and delivered a 3,450 gram stillborn fetus. Kleihauer-Betke testing performed and revealed massive fetomaternal hemorrhage with a result of 5.4-6.0%. The calculated fetomaternal hemorrhage was estimated to be 281.6 mL (approaching the total estimated fetal blood volume of 293 mL). The patient received 3 vials of intramuscular RhIG (300 μg/vial), 2 vials of intravenous RhIG (1,000 μg/vial), and 1 vial of intravenous RhIG (300 μg/vial) for a total RhIG dose of 3,200 μg, over a 3-day period, with no adverse clinical sequelae. Serological investigations for anti-D antibodies remained positive until 6 months and were inconclusive at 8 months postpartum. At 10 months postpartum, she was 9 weeks pregnant and no anti-D antibodies were detected. With this subsequent pregnancy, she was treated with routine RhIG and delivered a healthy RhD positive neonate.
conclusionAdequate dosing of RhIG can be achieved to prevent alloimmunization, even in massive fetomaternal hemorrhages. After large doses of RhIG, anti-D antibodies may persist for several months and do not necessarily indicate maternal alloimmunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.